Theraflu Disclaimer Exceeds NAD Expectations For Consumer Comprehension
This article was originally published in The Tan Sheet
Executive Summary
Novartis’ substantiation fails to support onset of action claims for Theraflu Multi-Symptom Severe Cold in TV, online and print ads, according to a NAD review of a challenge by Pfizer. NAD says a disclaimer in the ads contradicted rather than limited an onset of action claim, and likely was missed by consumers anyway.